StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 4/25/2014, (NASDAQ:MRK), $57.53 +0.03, +0.05%, "BUY" Merck & Compan Stock
 




  
  

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   4/25/2014   StockRing.com recommends to   "BUY"   MRK   stock at current price of   $57.53.
Today MRK stock opened at $57.32 and was trading in the daily range of $ 216030 per share.
Merck & Compan (NASDAQ:MRK) Market capitalization is $169.2B. MRK average daily volume is N/A.
On last trading session MRK stock traded 6,714,791 shares. Also the Short Ratio for (NASDAQ:MRK) stock is 44.033B.
Last year Merck & Compan(NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $58.31 on revenue of $3.38.
MRK 50-Day Moving Average is $15.668B vs. $57.53 now and 200-Day Moving Average is $56.23 vs. $57.53.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "BUY".  S&P 500 is "BUY" on  4/17/2014
--------------------------------------------------------------------------------------------------------------------
MRK Earnings Per Share - EPS (ttm) is 1.47. MRK Stock Price Per Earnings ratio - P/E is 39.12.
Merck & Compan(NASDAQ:MRK) stock pays a dividend of $ " per share which is a yield of "NYSE"%.
On average analysts predict that One Year Target Estimated price for MRK stock is $51.75.
In the last 52 weeks MRK stock was trading in the range of $44.60 - 58.32.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4573 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 4/17/2014 1:36:28 AM
2. DOW30+    Part 2    192 Stocks    Updated: 4/17/2014 1:50:47 AM
3. DOW30+    Part 3    193 Stocks    Updated: 4/17/2014 1:55:09 AM
4. DOW30+    Part 4    195 Stocks    Updated: 4/17/2014 1:59:27 AM
 
5. ENERGY    Part 1    188 Stocks    Updated: 4/18/2014 10:46:27 AM
6. ENERGY    Part 2    186 Stocks    Updated: 4/18/2014 10:51:32 AM
7. ENERGY    Part 3    196 Stocks    Updated: 4/18/2014 10:56:58 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 4/16/2014 2:02:40 AM
9. HEALTH    Part 2    138 Stocks    Updated: 4/16/2014 2:07:27 AM
 
10. FINANCE    Part 1    191 Stocks    Updated: 11/13/2013 10:58:43 AM
11. FINANCE    Part 2    193 Stocks    Updated: 11/13/2013 12:29:31 PM
12. FINANCE    Part 3    188 Stocks    Updated: 11/13/2013 12:42:47 PM
13. FINANCE    Part 4    188 Stocks    Updated: 11/13/2013 12:46:35 PM
14. FINANCE    Part 5    190 Stocks    Updated: 11/13/2013 10:52:57 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 4/24/2014 1:06:54 AM
16. SERVICE    Part 2    186 Stocks    Updated: 4/24/2014 1:11:49 AM
17. SERVICE    Part 3    183 Stocks    Updated: 4/24/2014 1:19:16 AM
18. SERVICE    Part 4    193 Stocks    Updated: 4/24/2014 1:33:13 AM
 
19. TECH    Part 1    187 Stocks    Updated: 4/17/2014 11:25:01 PM
20. TECH    Part 2    183 Stocks    Updated: 4/17/2014 11:29:45 PM
21. TECH    Part 3    185 Stocks    Updated: 4/17/2014 11:34:24 PM
22. TECH    Part 4    102 Stocks    Updated: 4/17/2014 11:37:10 PM
 
23. IPOs    200 Stocks    Updated: 4/18/2014 7:17:48 PM
 
24. ETFs    Part 1    193 Stocks    Updated: 4/21/2014 5:56:28 PM
25. ETFs    Part 2    191 Stocks    Updated: 4/21/2014 6:05:32 PM
26. ETFs    Part 3    157 Stocks    Updated: 4/22/2014 2:46:24 AM

BUY  DOW 30+:    ENERGY: CDW  CBA  TSRE  QIWI  EIGI     HEALTH: IEZ  EPHE  FM  JKF  IEO 
      FINANCE: XLK  DWX  GII  SRLN  SLY     SERVICES: TQQQ  MLPX  GLL  DDM  CNPF     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: GGB     ENERGY: MKTO  Q  HASI  SRLP  TSC     HEALTH: EMFN  MUAC  ISHG  GNMA  SLVP 
      FINANCE: GOVT  SLQD  PGM  JJU  XVZ     SERVICES: UST  YCL  SRTY  MYY  UVXY     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

BUY  DOW 30+:    ENERGY: WPT  WBB  VOYA  VMEM  TSRE     HEALTH: WOOD  TZW  TZV  TZE  TZD 
      FINANCE: XTN  XTL  XSW  XSD  XPH     SERVICES: ZSL  YCS  UYM  UWM  UWC     TECH: WDC  SWIR  RENN  ONNN  NTAP 
SELL  DOW 30+: GGB     ENERGY: XON  XGTI  UBIC  TSC  TNDM     HEALTH: TLH  SLVP  SHV  RING  MUAE 
      FINANCE: XVZ  VXZ  VXX  SLQD  SIL     SERVICES: YCL  VIXY  UVXY  UST  ULE     TECH: YNDX  XRX  XLNX  WIT  WCC 

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



4/25/2014  Friday, April 25, 2014 (Irvine, California) Today StockRing.com Recommendation is to "BUY"for Merck & Compan (NASDAQ:MRK) Stock. MRK stock opening price was $57.32 per share. Current price of NASDAQ:MRK Stock is $57.53 per share and it is $+0.03, (+0.05%) today and it was trading in the daily range of $216030 per share. Current Bid Price for (NASDAQ:MRK) stock is $3.03 and the Ask Price is $56.65. In the last 52 weeks MRK stock was trading in the range of $44.60 - 58.32. 50-Day Moving Average for (NASDAQ:MRK) stock is $15.668B and 200-Day Moving Average is $56.23. On average analysts predict that One Year Target Estimated price for (NASDAQ:MRK) stock is $51.75.

Merck & Compan (NASDAQ:MRK) is rated as a buy on 4/17/2014 1:36:28 AM.

Merck & Compan (NASDAQ:MRK) Market capitalization is $169.2B. (NASDAQ:MRK) stock average daily volume is N/A shares per day. However, on last trading session of Apr 24, 2012 MRK stock traded 6,714,791 shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:MRK) stock is 44.033B. On previous trading session MRK Stock closed at $57.50 per share.

Last year Merck & Compan (NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $58.31 on total revenue of $3.38. Earnings Per Share - EPS (ttm) for MRK stock is 1.47. Also, (NASDAQ:MRK) Stock Price Per Earnings ratio - P/E is 39.12. Thus, (NASDAQ:MRK) Stock Price/Sales (ttm) ratio is 57.50 and Price/Book (mrq) ratio is 3.84.

(NASDAQ:MRK) Stock pays a dividend of $ " per share which is a yield of "NYSE"%. So at this time (NASDAQ:MRK) Stock maintains Trailing Annual Dividend Rate at 2.50.


StockRing Recommendations for Merck & Compan (NASDAQ:MRK) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=MRK

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/25/2014 1 Year Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 25, 2014
  
1 Year MRK 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
4/25/2014 5 days Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 25, 2014
  
5 Days MRK 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/25/2014 Stock market price quote data for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 25, 2014

Last Trade: 57.53
Trade Time: Apr 24
Change: +0.03, (+0.05%)
Prev Close: 57.50
Open: 57.32
Bid: 3.03
Ask: 1.74
1y Target Est: $51.75
50-Day Moving Average: 15.668B
200-Day Moving Average:
56.23
Short Ratio: 44.033B
Trailing Annual Dividend Rate: 2.50
Day's Range: 216030
52wk Range: 44.60 - 58.32
Volume: 6,714,791
Avg Vol: N/A
Market Cap: 169.2B
P/E (ttm): 39.12
EPS (ttm): 1.47
Div & Yield: " ("NYSE"%)
Revenue (ttm): 3.38
Earnings before Tax (EBITDA) (ttm): 58.31
Price/Sales (ttm): 57.50
Price/Book (mrq): 3.84
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

MERCK CO INC(NYSE: MRK) Company Information

Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station, NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com

MERCK CO INC(NYSE: MRK) DETAILS

MERCK CO INC(NYSE: MRK) Index Membership: Dow Jones Composite Dow Industrials S&P 100 S&P 500 S&P 1500 Super Comp
MERCK CO INC(NYSE: MRK) Sector: Healthcare
MERCK CO INC(NYSE: MRK) Industry: Drug Manufacturers - Major
MERCK CO INC(NYSE: MRK) Full Time Employees: 52,700

MERCK CO INC(NYSE: MRK) BUSINESS SUMMARY

Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

MERCK CO INC(NYSE: MRK) KEY EXECUTIVES

Mr. Richard T. Clark , 63 Exec. Chairman, Chief Exec. Officer and Pres $ 4.03M $ 0

Mr. Peter N. Kellogg , 52 Chief Financial Officer and Exec. VP $ 1.60M $ 0

Mr. Kenneth C. Frazier , 54 Exec. VP and Pres of Global Human Health $ 2.00M $ 0

Dr. Peter Kim Ph.D., 50 Exec. VP and Pres of Merck Research Laboratories $ 1.91M $ 0

Mr. Bruce N. Kuhlik , 52 Exec. Vice president and Gen. Counsel $ 1.25M $ 0



4/25/2014 Latest stock market news data for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 25, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

Merck & Co., Inc. (NYSE:MRK): Another Milestone In Immunotherapy
WallStreetPR - 20 hours ago
Boston, MA 04/24/2014 (wallstreetpr) - The U.S. Food and Drug Administration (FDA) have approved Merck & Co., Inc. (NYSE:MRK)'s Ragwitek to treat allergy in adult patients. The medicine is a new approach to treating patients suffering allergic rhinitis ...
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences ...
Motley Fool - Apr 15, 2014
While leader Gilead Sciences (NASDAQ: GILD ) waits on the FDA review for its combination of Sovaldi and levipasvir, and battles questions over Sovaldi's price tag, Merck is producing data on easy-to-treat populations and Bristol-Myers Squibb has turned ...
Merck & Co., Inc. (NYSE:MRK): Gets The FDA Approval for RAGWITEK™
USTrade Voice - Apr 23, 2014
Dallas, Texas 04/23/2014 (ustradevoice) - Merck & Co., Inc. (NYSE:MRK) have received the FDA Approval for RAGWITEK™.
Merck & Co Inc (NYSE:MRK) – Merck and Award-Winning Actress S. Epatha ...
Jutia Group - Apr 23, 2014
Merck & Co Inc (NYSE:MRK) [PR Newswire] - WHITEHOUSE STATION, N.J., April 23, 2014 /PRNewswire/ - Merck (MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning ...
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.
Schaeffers Research - Apr 7, 2014
Pharmaceutical giants GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) have charted different paths during the last year.
Insider Selling: Merck & Co. Insider Unloads 145225 Shares of Stock (MRK) - Ticker Report
Drug Manufacture Most Active: Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK ...
Gaining Green - 18 hours ago
Pfizer Inc. (NYSE:PFE) announced top-line results from two pivotal phase 3 trials from the oral treatment Psoriasis Trials (OPT) programme, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an ...
Stocks to Watch Friday: Merck & Co., Inc., Deere & Company, and Toyota Motor ...
Schaeffers Research (blog) - Apr 10, 2014
Momentum names that made notable moves on Thursday and could continue to do so into Friday's session include pharmaceutical firm Merck & Co., Inc. (NYSE:MRK), machinery concern Deere & Company (NYSE:DE), and automaker Toyota Motor Corp ...
Merck & Co. Price Target Increased to $70.00 by Analysts at MKM Partners (MRK) - Ticker Report
Drug Most active stocks: Pfizer Inc. (NYSE:PFE), Merck & Co (NYSE:MRK ... - Gaining Green
Merck & Co., Inc. (NYSE:MRK) Reports Positives on its Hepatitis Treatment
USTrade Voice - Apr 11, 2014
Dallas, Texas 04/11/2014 (ustradevoice) - Merck & Co., Inc. (NYSE:MRK) continues to surge in the market after the company announced positive news, on the progress being made on the development of its hepatitis C combo therapies MK-5172 AND ...
Merck Hepatitis C combo pill impresses in Phase II - Seeking Alpha
Merck Data Show Potent Rival to Gilead's Hepatitis C Pill - Bloomberg
Merck & Co., Inc. (NYSE:MRK)'s Oncology Break-Through MK-3475 Said To ...
WallStreetPR - Apr 9, 2014
It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK) called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC).
Dividend Stocks To Buy Right Now [Merck & Co., Inc., Duke Energy Corp ...
ETF Daily News - Apr 21, 2014
Companies increased dividend payouts by a robust $17.8 billion in Q1 2014, compared to a $14.5 billion increase in Q1 of 2013, a 14.2% year-over-year increase, according to S&P Indices.

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


4/25/2014 News from StockRing Blog about Merck & Compan (NASDAQ:MRK) Stock on Friday, April 25, 2014



Copyright © 2012 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.